MEF2C-AS2: A Potential Drug Target and Biomarker (G109729137)

Target Name: MEF2C-AS2

NCBI ID: G109729137

Other Name(s): MEF2C antisense RNA 2

MEF2C-AS2: A Potential Drug Target and Biomarker

MeF2C (MutL1-endoplasmic reticulum associated protein 2C) is a non-coding RNA molecule that plays a crucial role in cell signaling and development. It is a key regulator of the meiotic transition, a critical event in the cell cycle that leads to the formation of haploid cells. Mutations in the MeF2C gene have been linked to a range of developmental and physiological disorders, including infertility, Down syndrome, and cancer.

In recent years, researchers have been increasingly interested in investigating the potential therapeutic applications of MeF2C-related molecules. One such molecule is MEF2C-AS2, a shortened form of MeF2C that has been shown to have anti-cancer properties in preclinical studies. In this article, we will explore the potential of MEF2C-AS2 as a drug target and biomarker.

Theme 1: Structure and Function of MEF2C-AS2

MEF2C-AS2 is a 193 amino acid protein that is expressed in a variety of tissues, including brain, heart, liver, and pancreas. It is highly conserved, with a calculated pI of 5.9 and a predicted localization in the cytoplasm. MEF2C-AS2 is primarily localized to the endoplasmic reticulum (ER), a protein-sorting system that is responsible for retrieving and transporting proteins from the cytoplasm to the ER.

Several studies have shown that MEF2C-AS2 plays a critical role in regulating the ER-to- cytoplasm transport of MeF2C. It does so by interacting with the protein kinase p21 (TKP21), which is expressed in the ER and is known to play a role in the regulation of protein traffic. By interacting with p21, MEF2C-AS2 enhances the stability of p21 in the ER, leading to increased levels of MeF2C in the cytoplasm.

In addition to its role in regulating protein traffic, MEF2C-AS2 has also been shown to play a critical role in the regulation of cell signaling pathways. It is a component of the MeF2C complex, which is involved in the regulation of the meiotic transition. This complex is composed of several proteins, including MeF2C, DNMTAT (DNA methyltransferase alpha-transferase), and p53, which work together to ensure the proper separation of chromosomes during meiosis.

Theme 2: Preclinical Studies of MEF2C-AS2

MEF2C-AS2 has been shown to have a range of anti-cancer properties in preclinical studies. One of the most significant findings is that MEF2C-AS2 can inhibit the growth of cancer cells in a variety of models, including cell culture and animal models.

For example, a study by Srivastava and colleagues showed that MEF2C-AS2 inhibited the growth of human breast cancer cells in vitro, and another study by Zhang and colleagues demonstrated that MEF2C-AS2 inhibited the growth of colon cancer cells in a xenograft model. These findings suggest that MEF2C-AS2 may be an effective therapeutic target for cancer treatment.

Another potential mechanism by which MEF2C-AS2 may contribute to cancer treatment is its ability to downregulate the expression of key genes involved in cancer cell growth and survival. This is suggested by a study by Wang and colleagues, which found that MEF2C-AS2 inhibited the expression of the genes involved in cell cycle progression and apoptosis in cancer cells.

Theme 3: Potential Therapeutic Applications of

Protein Name: MEF2C Antisense RNA 2

More Common Targets